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TaiwanBackground: The data on susceptibility of important cephalosporins against four Enterobacter-
iaceae members producing potential extended-spectrum b-lactamase (ESBL) collected from
Taiwanese intensive care units are lacking.
Methods: Minimum inhibitory concentrations (MICs) of cefotaxime, ceftazidime, and cefepime
were determined using agar dilution method, against Escherichia coli (n Z 344), Klebsiella
pneumoniae (n Z 359), Enterobacter cloacae (nZ 103), and Proteus mirabilis (nZ 78). Sus-
ceptibilities of these isolates to three cephalosporins were assessed according to MIC break-
points recommended by the Clinical and Laboratory Standards Institute (CLSI) and the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 2013. The double-
disk synergy test using disks containing cefepime (30 mg) with or without clavulanate (10 mg)
was applied to confirm production of ESBL for isolates with cephalosporin MIC 2 mg/mL.
Results: A total of 175 isolates were verified as ESBL producers. The rates of cefepime suscep-
tibility among the ESBL-producing isolates, according to CLSI (EUCAST) criteria, were 56.7%
(22.4%) for E. coli, 61.3% (12.0%) for K. pneumoniae, 57.9% (31.6%) for E. cloacae, and 71.4%
(7.1%) for P. mirabilis. Using different cefepime MIC breakpoints (MICs 16 mg/mL recom-
mended by CLSI criteria and 2 mg/mL by EUCAST criteria) to define nonsusceptibility, we
found that both criteria were poorer at predicting ESBL producers among K. pneumoniae
and E. cloacae than among the other two species. In addition, we also found that the cefepime
MIC level of 1.0 mg/mL best distinguished non-ESBL- from ESBL-producing K. pneumoniae and
E. cloacae.
Conclusion: To detect ESBLs, CLSI should revise the cefepime MIC breakpoint against Entero-
bacteriaceae.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
During the past three decades, Gram-negative bacilli
(GNBs) have gradually become resistant to a number of
antibiotics.1,2 Of greatest concern are the extended-
spectrum b-lactamase (ESBL) producers. In 2010, the
Clinical and Laboratory Standards Institute (CLSI) updated
the breakpoints of minimum inhibitory concentrations
(MICs) of third-generation cephalosporins against Enter-
obacteriaceae and omitted ESBL confirmation.3 Neverthe-
less, detection of ESBL producers among clinical isolates ofGNBs remains an important issue for infection control,
especially in intensive care units (ICUs), where infections
due to ESBL-producing bacteria are associated with dismal
clinical outcome.4,5
Cefepime has been advocated as an alternative to car-
bapenems for the treatment of infections due to ESBL-
producing GNBs.6 However, Lee et al7 demonstrated that
cefepime, when used to treat patients with bacteremia
caused by the ESBL-producing Enterobacteriaceae with
cefepime MIC values of 2e8 mg/mL, was associated with
high mortality. In addition, most studies on susceptibility of
Cefepime MIC susceptibility and ESBL detection 87ESBL-producing isolates to cefepime have focused on
Escherichia coli and Klebsiella spp., and ignored Enter-
obacter cloacae and Proteus mirabilis,8,9 which are also
known to produce ESBLs.10 Because of the inconsistency
between in vitro susceptibility to cefepime and failure to
eradicate ESBL-producing GNBs in vivo, we decided to
investigate the cefepime MIC profile in Enterobacteriaceae
with high potential for ESBL production.
The ongoing nationwide Surveillance for Monitoring
Antimicrobial Resistance in Taiwan (SMART), initiated since
2000, was designed to monitor longitudinally the in vitro
antimicrobial susceptibility of clinically important patho-
gens. In Taiwan, until 2011 the prevalence of important
metallo-b-lactamases (VIM, IMP, NDM, etc.) was virtually
low among Enterobacteriaceae.11 In addition, Klebsiella
pneumoniae carbapenemase-producing GNBs was first
detected in 2009.12 Therefore, we chose the ICU isolates of
enteric GNBs collected in 2007 to survey the MIC distribu-
tions of third- and fourth-generation cephalosporins against
ESBL-producing Enterobacteriaceae. Furthermore, with
regard to predicting the ESBL production among four
potentially ESBL-producing Enterobacteriaceae species, we
used their cefepime MIC distribution patterns to estimate
the sensitivity and specificity of different cefepime MIC
nonsusceptibility breakpoints recommended in 2013.
Finally, we applied the statistical analyses to find out the
optimal cefepime MIC cutoff value for detecting the ESBL
existence. This is part of the study of SMART 2007.
Methods
Bacterial isolates
The isolates evaluated in this study comprised 884
consecutive, nonduplicate Enterobacteriaceae isolates
collected from various clinical specimens from patients
(one isolate per patient) in ICUs at 10 major teaching hos-
pitals in Taiwan (Northern Taiwan, n Z 4; Central Taiwan,
n Z 1; Southern Taiwan, n Z 5) from July 1, 2007 to
December 31, 2007. The isolates included E. coli (nZ 344),
K. pneumoniae (n Z 359), E. cloacae (n Z 103), and P.
mirabilis (n Z 78). All isolates were stored at 70 C in
Trypticase soy broth (Difco Laboratories, Detroit, MI, USA)
supplemented with 15% glycerol prior to testing. They were
then transported to the National Taiwan University Hospital
for further identification by standard methods. The isolates
were identified using the Phoenix PMIC/ID-30 identification
system (Becton Dickinson Systems, Sparks, MD, USA).
Antimicrobial susceptibility testing
The MICs of cefotaxime, ceftazidime, and cefepime against
all isolates were determined by the agar dilution method
according to CLSI guidelines.3 E. coli ATCC 25922 and
Pseudomonas aeruginosa ATCC 27853 were used as
quality-control strains for each run of MIC tests. MIC testing
was repeated if the results for ATCC strains were
outside the expected range recommended by the CLSI.3
The MIC breakpoint criteria recommended by the CLSI and
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) in 20133,13 were applied to interpret thesusceptibility profiles of bacteria under evaluation to
cefotaxime, ceftazidime, and cefepime.
Detection of ESBL production
The potential ESBL producers (E. coli, K. pneumoniae, E.
cloacae, and P. mirabilis) with phenotypically cefotaxime or
ceftazidime MICs2 mg/mLwere tested for ESBL production.
Traditional ESBL confirmation methods, using a disk con-
taining 30-mg ceftazidime (or cefotaxime), alone or in com-
bination with a 10-mg clavulanate disk, are known to have low
sensitivity for detecting bacteria that produce AmpC b-lac-
tamase.14 Therefore, in this study we used the modified
double-disk synergy test (DDST), which involves a disk con-
taining 30 mg cefepime,with orwithout clavulanic acid (10-mg
disk; with a center-to-center distance of 30 mm) instead of a
disk containing 4-mg clavulanic acid,15 to detect ESBL pro-
ducers. The production of ESBL was considered positive if the
diameter of the cefepime disk increased by 5 mm, or the
zone expansion was 50% of the original size. The latter
standard was suggested by M’Zali et al16 who used third-
generation cephalosporin  clavulanate (10-mg) to detect
ESBLs among enteric GNBs.
Statistical analysis
The sensitivity and specificity of detecting ESBL production
among four ESBL-producing Enterobacteriaceae species (E.
coli, K. pneumoniae, E. cloacae, and P. mirabilis) were
calculated using CLSI 2013 and EUCAST 2013 MIC break-
points for nonsusceptibility to cefepime. If low ESBL
detection sensitivity was recognized for specific enteric
GNBs, the accuracy of the cefepime MIC profile to predict
ESBL was further investigated by calculating the area under
the receiver operating characteristic (ROC) curve, which
provides an overall index of diagnostic accuracy from a
plot of sensitivity against the false-positive rate (i.e., 1 e
specificity) for all cefepime MIC values. Then, the Youden
index [sensitivity e (1 e specificity)] was calculated to
determine the optimal MIC cutoff point, that is, selecting
the maximum result of sensitivity plus specificity, which
corresponded to a cefepime MIC level that best detected
ESBL production. If appropriate, the Fisher exact test was
applied to compare differences in percentages of categor-
ical variables. A p value <0.05 was considered to indicate
statistical significance. All analyses were conducted using
the statistical package SPSS version 17 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
The rate of ESBL production among Enterobacteriaceae
species in 2007 was 19.5% for E. coli (n Z 67), 20.9% for K.
pneumoniae (n Z 75), 18.4% for E. cloacae (n Z 19), and
17.9% for P. mirabilis (n Z 14). A bar plot comparing the
susceptibility of ESBL-producing GNBs species with that of
non-ESBL-producing species to cefepime is shown in Fig. 1.
Although all GNBs species, regardless of status of ESBL
production, showed cefepime susceptibility rates greater
than 55%, there were significant differences in rates of
susceptibility to that of antibiotics among all members of
Figure 1. Proportions of susceptibilities of cefepime against
ESBL- and non-ESBL-producing Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae, and Proteus mirabilis.
ESBL Z extended-spectrum b-lactamase.
88 S.-S. Jean et al.the Enterobacteriaceae family. The MIC distributions of
three antimicrobials against the four members of Enter-
obacteriaceae with ESBL production are illustrated in
Table 1. We noted that marked differences between rates
of susceptibility to cefepime based on CLSI 2013 criteria
and rates based on EUCAST 2013 criteria existed among E.
coli, K. pneumoniae, and P. mirabilis. In addition, more
than 70% of the ESBL-producing P. mirabilis strains were
susceptible to ceftazidime. The majority of isolates of all
four species showed poor susceptibility to cefotaxime. Re-
sults of the DDST of all Enterobacteriaceae isolates that
were tested positive for ESBL production revealed that the
CLSI and EUCAST nonsusceptibility breakpoints for cefe-
pime were less sensitive at detecting ESBL production
among K. pneumoniae (60e68%) and E. cloacae (28e54%)
than among the other two GNBs species (Table 2). In
addition, better positive predictive values of EUCAST 2013
criteria for detecting ESBL production are noted amongTable 1 Susceptibilities of 175 ESBL-producing Enterobacteriac
Bacteria
(no. of
isolates)
Agent No. of isolates with indicat
0.03 0.06 0.12 0.25 0.5 1 2 4
Escherichia
coli
(n Z 67)
Cefotaxime 0 1 0 1 1 2 1 4
Ceftazidime 0 0 0 1 3 6 8 4
Cefepime 0 0 0 5 9 1 5 8
Klebsiella
pneumoniae
(n Z 75)
Cefotaxime 0 2 0 0 0 2 1 3
Ceftazidime 0 0 0 0 5 3 3 4
Cefepime 0 1 2 1 3 2 9 12
Enterobacter
cloacae
(n Z 19)
Cefotaxime 0 0 0 0 0 0 0 3
Ceftazidime 0 0 0 1 0 0 0 2
Cefepime 0 0 0 0 3 3 0 4
Proteus
mirabilis
(n Z 14)
Cefotaxime 0 0 0 0 0 0 1 3
Ceftazidime 0 0 7 3 0 0 1 0
Cefepime 0 0 0 0 1 0 0 6
* p < 0.05.
CLSI Z Clinical and Laboratory Standards Institute; ESBL Z exten
Antimicrobial Susceptibility Testing; MIC Z minimum inhibitory conceE. coli, K. pneumoniae, and P. mirabilis strains than those
of CLSI 2013 criteria (Table 2).
Based on the results of the area under the ROC curve
analysis, we found that cefepime MIC values were more
predictive of ESBL production among isolates of K. pneu-
moniae [area under ROC curve: 0.892; 95% confidence in-
terval (CI): 0.852e0.940] than among isolates of E. cloacae
(area under ROC curve: 0.743; 95% CI: 0.622e0.864) (Fig. 2A
and B). In addition, cefepime MIC values with a cutoff value
1.0 mg/mL provided the best compromise between
sensitivity and specificity for detecting ESBLs in both K.
pneumoniae and E. cloacae (Table 3).
Discussion
In this study, a number of ESBL-producing enteric GNBs
isolates were found to be susceptible to cefepime. In
addition, among the E. cloacae and K. pneumoniae isolates
with ESBL production, the current CLSI and EUCAST cefe-
pime MIC nonsusceptible breakpoints were not robust
enough to differentiate between non-ESBL producers and
ESBL producers. Among Enterobacteriaceae spp., although
the CLSI does not consider the importance of ESBL detec-
tion, the EUCAST considers it mandatory for epidemiolog-
ical purposes. We found that the rates of susceptibility to
cefepime for ESBL-producing E. coli and K. pneumoniae
species were significantly higher among isolates obtained
from the patients in ICUs during 2007 in Taiwan (56.7% for
E. coli and 61.3% for K. pneumoniae) than those among
isolates collected from the patients in two recently re-
ported surveys conducted in the Asia-Pacific region.9,17
In one study conducted in China, Wang et al18 reported
that CTX-M-type ESBLs were predominant amongst isolates
of Enterobacteriaceae species (>90% for E. coli and P.
mirabilis, and approximately two-thirds for K. pneumo-
niae), which showed a high degree of nonsusceptibility toeae isolates against three cephalosporins
ed MIC (mg/mL) MIC (mg/mL) Susceptible rates
(%),
evaluated by
8 16 32 64 128 >128 50% 90% CLSI 2013
(M100-S23)
EUCAST
2013
4 5 9 8 11 20 64 >128 7.5 7.5
10 13 15 5 1 1 16 64 32.8* 14.9
10 13 9 4 3 0 8 64 56.7* 22.4
9 12 17 9 10 10 32 >128 5.3 5.3
4 8 3 6 7 32 128 >128 20 10.7
16 9 6 8 4 2 8 64 61.3* 12.0
4 1 2 3 3 3 32 >128 0 0
0 0 3 3 2 8 128 >128 15.8 5.3
1 5 1 0 0 2 4 >128 57.9 31.6
3 4 2 0 1 0 8 32 0 0
0 0 2 1 0 0 0.12 32 78.6 71.4
3 3 1 0 0 0 4 16 71.4* 7.1
ded-spectrum b-lactamase; EUCAST Z European Committee on
ntration.
Table 2 Performance parameters of estimating the sensitivity, specificity, positive, and negative predictive values after use of various nonsusceptibility MIC breakpoints to
cefepime for detection of ESBL production, among 884 clinical isolates of Enterobacteriaceae (Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae, and Proteus mirabilis)
Bacterial spp.
(no. of isolates)
Judgment breakpoints
(cefepime MIC, mg/mL)
True False Sensitivity
(%)
Specificity
(%)
Positive predictive
value (%)
Negative predictive
value (%)Positive
(no.)
Negative
(no.)
Positive
(no.)
Negative
(no.)
E. coli (344) CLSI, R þ I (non-S, 16) 29 271 38 6 82.9 87.7 62.0 95.5
CLSI, R (32) 16 273 51 4 80.0 84.3 55.2 94.6
EUCAST, non-S (2) 52 260 15 17 75.4 94.5 76.8 94.1
K. pneumoniae (359) CLSI, R  I (non-S, 16) 29 268 46 16 64.4 85.4 53.8 90.1
CLSI, R (32) 20 271 55 13 60.6 83.1 48.6 88.9
EUCAST, non-S (2) 66 253 9 31 68.0 96.6 84.1 92.0
E. cloacae (103) CLSI, R  I (non-S, 16) 8 77 11 7 53.3 87.5 49.1 89.2
CLSI, R (32) 3 78 16 6 33.3 83.0 30.7 84.6
CLSI, R (32) 13 52 6 32 28.8 89.7 38.7 84.8
P. mirabilis (78) CLSI, R  I (non-S, 16) 4 63 10 1 80.0 86.3 56.0 95.2
CLSI, R (32) 1 64 13 0 100 81.0 53.4 100
EUCAST, non-S (2) 13 61 1 3 81.3 98.4 89.9 96.0
Overall (884) CLSI, R  I (non-S, 16) 70 679 105 30 70.0 86.6 56.3 92.1
CLSI, R (32) 40 686 135 23 63.5 83.6 48.9 90.3
EUCAST, non-S (2) 144 626 83 83 63.4 88.3 57.2 90.7
CLSIZ Clinical and Laboratory Standards Institute; EUCASTZ European Committee on Antimicrobial Susceptibility Testing; IZ intermediate; MICZ minimum inhibitory concentration;
non-S Z non-susceptible; R Z resistant.
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Figure 2. (A) Discrimination power (area under the receiver operating characteristic curve) of the distributions of cefepime
minimum inhibitory concentrations (MICs) for predicting the extended-spectrum b-lactamase (ESBL) phenotype of Klebsiella
pneumoniae, and (B) Enterobacter cloacae isolates. ROC Z receiver operating characteristic.
90 S.-S. Jean et al.cefepime. High rates of susceptibility to cefepime were
also reported for ESBL-producing E. coli and K. pneumoniae
in Taiwan, and for other ESBL producers without CTX-M
predominance in the United States.19 In addition, we
found that 67% of ESBL-producing E. cloacae isolates were
susceptible to cefepime, which is comparable with the re-
sults reported by Szabo´ et al.20 Therefore, based on the
present CLSI MIC interpretive criteria, the susceptibility toTable 3 The sensitivities, specificities, and Youden in-
dexes of various categories of cefepime MICs for recognizing
the existence of ESBL phenotype among Klebsiella pneu-
moniae and Enterobacter cloacae isolates
Cefepime MIC
level (mg/mL)
Sensitivity 1 e Specificity Youden
index
K. pneumoniae
<0.50 1.000 1.000 0.000
0.50 0.933 0.179 0.754
1.0 0.927 0.130 0.797
2.0 0.880 0.109 0.771
4.0 0.760 0.088 0.672
8.0 0.600 0.063 0.537
16.0 0.387 0.056 0.331
32.0 0.000 0.000 0.000
E. cloacae
<0.50 1.000 1.000 0.000
0.50 0.861 0.441 0.420
1.0 0.842 0.393 0.449
2.0 0.684 0.381 0.303
4.0 0.684 0.369 0.315
8.0 0.474 0.167 0.307
16.0 0.421 0.107 0.314
32.0 0.000 0.000 0.000
CLSI Z Clinical and Laboratory Standards Institute;
ESBL Z extended-spectrum b-lactamase; MIC Z minimum
inhibitory concentration.cefepime did not parallel with excluding the existence
of ESBL production in Enterobacteriaceae. According to
the pattern of cefepime MIC distributions of Enter-
obacteriaceae in this SMART study conducted in 2007, ESBLs
of the non-CTX-M type sparing CTX-M-9 were dominant
among the ESBL-producing isolates of K. pneumoniae,18,21
and the majority of E. cloacae strains harbored the SHV
type of b-lactamase. The findings regarding E. cloacae were
similar to those reported in Taiwan by Yu et al22 and Liu
et al.23 Besides, we observed that the P. mirabilis isolates
in our study were highly susceptible to cefepime and cef-
tazidime, which is consistent with data reported by Wang
et al.18 Grossly, a substantial number of ESBL-producing
species were sensitive to cefepime, which reflects the
considerably variable hydrolyzing spectra of ESBLs against a
variety of cephalosporins.
In general, for E. cloacae and other Enterobacteriaceae
species of potentially plasmidic AmpC b-lactamase pro-
ducers (including E. coli, P. mirabilis, and K. pneumo-
niae),24 cefepime is considered in vitro effective against
them.10 Polsfuss et al8 found that DDST performed against
cefepime plus clavulanate had an overall sensitivity of
96.6% and a specificity of 89.8% at detecting ESBL producers
among Enterobacteriaceae species. Similar findings were
also reported by Stu¨renburg et al.14 By contrast, Tzelepi
et al15 demonstrated that the same DDST (spaced 30 mm)
was not sensitive at detecting ESBL-producing Enterobacter
species. However, they found that 10 (32%) of 31 Enter-
obacter isolates were non-SHV-type ESBL producers,15
indicating that DDST performed against cefepime is not
sensitive at detecting ESBL production for Enterobacter
species. Reduction of the disk distance from 30 mm to
20 mm in DDST has been shown to improve the detection
rate of ESBL among Enterobacter species.15 Interestingly,
we found that the current EUCAST MIC breakpoint of
1.0 mg/mL for cefepime increased the sensitivity of
detecting ESBL producers among isolates of E. cloacae and
K. pneumoniae, indicating that the CLSI should re-evaluate
its MIC breakpoints for detecting ESBLs. Similar suggestion
was also proposed by Chin et al25 previously.
Cefepime MIC susceptibility and ESBL detection 91In conclusion, using the MIC nonsusceptibility criteria for
cefepime recommended by CLSI and EUCAST in 2013, we
found that both criteria had poor sensitivity in detecting
ESBL production among E. cloacae and K. pneumoniae iso-
lates, although the criteria provided acceptable sensitivity
for detecting ESBL production among E. coli and P. mirabilis
isolates. Analyses of the area under the ROC curve revealed
that a cefepime MIC value of 1 mg/mL was a reliable cutoff
level for differentiating ESBL-producing from non-ESBL-
producing K. pneumoniae and E. cloacae isolates.
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